David Topper - Nov 22, 2022 Form 4 Insider Report for Frazier Lifesciences Acquisition Corp (FLAC)

Role: Chief Financial Officer, Director
Signature: /s/ David Topper
Stock symbol: FLAC
Transactions as of: Nov 22, 2022
Transactions value $: $0
Form type: 4
Date filed: 11/23/2022, 03:31 PM
Next filing: Apr 11, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FLAC	Class B Ordinary Shares	Options Exercise		-30K	-100%		0	Nov 22, 2022	Class A Ordinary Shares	30K		Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

David Topper is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.

Content

Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.